Home LiteratureArticle Details
PMID: 21242887 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.

Current opinion in HIV and AIDS ·Vol. 6 ·No. 1 ·2011-01-00 ·Pages 4-11

Karn J

Abstract

Despite the remarkable success of intensive antiretroviral drug therapy in blocking the HIV replication, the virus persists in a small number of cells in which HIV has been transcriptionally silenced. This review will focus on recent insights into the HIV transcriptional control mechanisms that provide the biochemical basis for understanding latency. Latency arises when the regulatory feedback mechanism driven by HIV Tat expression is disrupted. Small changes in transcriptional initiation, induced by epigenetic silencing, can lead to restrictions in Tat levels and entry of proviruses into latency. In resting memory T-cells, which carry the bulk of the latent viral pool, additional restrictions limiting cellular levels of the essential Tat cofactor P-TEFb and the transcription initiation factors nuclear factor kappa B and nuclear factor of activated T cells ensure that the provirus remains silenced unless the host cell is activated. Strategies to purge the latent proviral pool require nontoxic activator molecules. The multiple restrictions imposed on latent proviruses that need to be overcome suggest that proviral reactivation will not be achieved when only a single reactivation step is targeted but will require both removal of epigenetic blocks and the activation of P-TEFb. Alternatively, new inhibitors that block proviral reactivation could be developed.

MeSH Terms
HIV/genetics,physiology Humans Transcription, Genetic Virus Latency tat Gene Products, Human Immunodeficiency Virus/antagonists & inhibitors,metabolism
Chemicals
tat Gene Products, Human Immunodeficiency Virus
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Karn Jonathan
Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA. jonathan.karn@case.edu
References (86)
86 references, click to expand
  1. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.
    EMBO J. 2007 Jan 24;26(2):412-23 PMID: 17245431
  2. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP).
    J Exp Med. 1998 Jun 15;187(12):2031-6 PMID: 9625762
  3. Duration of nuclear NF-kappaB action regulated by reversible acetylation.
    Science. 2001 Aug 31;293(5535):1653-7 PMID: 11533489
  4. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.
    J Virol. 2004 Feb;78(3):1160-8 PMID: 14722271
  5. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
    EMBO J. 2006 Jan 11;25(1):139-49 PMID: 16319923
  6. Contribution of the TATA motif to Tat-mediated transcriptional activation of human immunodeficiency virus gene expression.
    J Virol. 1992 Sep;66(9):5594-7 PMID: 1501293
  7. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 PMID: 9671771
  8. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein.
    J Virol. 1998 Oct;72(10):8252-6 PMID: 9733868
  9. Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+ T cells.
    J Biol Chem. 2002 Jun 28;277(26):23733-41 PMID: 11956207
  10. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells.
    EMBO J. 2009 May 20;28(10):1407-17 PMID: 19387490
  11. Determinants of the establishment of human immunodeficiency virus type 1 latency.
    J Virol. 2009 Apr;83(7):3078-93 PMID: 19144703
  12. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.
    Cell. 1998 Nov 25;95(5):595-604 PMID: 9845362
  13. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.
    Virology. 2009 Jun 20;389(1-2):20-5 PMID: 19447460
  14. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
    Science. 2010 Jul 9;329(5988):174-80 PMID: 20616270
  15. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1.
    J Virol. 2007 Jun;81(11):6043-56 PMID: 17376917
  16. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
    Cell. 1998 Feb 20;92(4):451-62 PMID: 9491887
  17. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.
    J Virol. 2010 Jul;84(13):6425-37 PMID: 20410271
  18. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.
    EMBO J. 2003 Dec 15;22(24):6550-61 PMID: 14657027
  19. Epigenetic regulation of HIV-1 latency by cytosine methylation.
    PLoS Pathog. 2009 Jun;5(6):e1000495 PMID: 19557157
  20. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity.
    Cell. 2005 Jul 29;122(2):169-82 PMID: 16051143
  21. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription.
    Mol Cell. 2010 May 14;38(3):428-38 PMID: 20471948
  22. Transcriptional interference antagonizes proviral gene expression to promote HIV latency.
    Cell Host Microbe. 2008 Aug 14;4(2):123-33 PMID: 18692772
  23. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
    Retrovirology. 2009 Jun 02;6:52 PMID: 19486542
  24. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.
    J Virol. 2004 Jun;78(12):6122-33 PMID: 15163705
  25. Retroviral DNA integration: viral and cellular determinants of target-site selection.
    PLoS Pathog. 2006 Jun;2(6):e60 PMID: 16789841
  26. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter.
    J Biol Chem. 2006 Jul 21;281(29):19960-8 PMID: 16687403
  27. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.
    J Virol. 2009 Sep;83(17):8470-81 PMID: 19535437
  28. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.
    EMBO J. 2003 Apr 15;22(8):1868-77 PMID: 12682019
  29. Pharmaceutical approaches to eradication of persistent HIV infection.
    Expert Rev Mol Med. 2009 Feb 11;11:e6 PMID: 19208267
  30. Generation of HIV latency during thymopoiesis.
    Nat Med. 2001 Apr;7(4):459-64 PMID: 11283673
  31. Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.
    Mol Cell Biol. 2002 Feb;22(4):1079-93 PMID: 11809800
  32. Primary cell model for activation-inducible human immunodeficiency virus.
    J Virol. 2007 Jul;81(14):7424-34 PMID: 17475639
  33. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.
    Nat Med. 2000 Jan;6(1):82-5 PMID: 10613829
  34. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3862-6 PMID: 8171003
  35. Crystal structure of HIV-1 Tat complexed with human P-TEFb.
    Nature. 2010 Jun 10;465(7299):747-51 PMID: 20535204
  36. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.
    EMBO J. 1993 Sep;12(9):3551-8 PMID: 8253080
  37. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.
    Nat Med. 2009 Aug;15(8):893-900 PMID: 19543283
  38. Structural basis of HIV-1 activation by NF-kappaB--a higher-order complex of p50:RelA bound to the HIV-1 LTR.
    J Mol Biol. 2009 Oct 16;393(1):98-112 PMID: 19683540
  39. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
    Nat Med. 2003 Jun;9(6):727-8 PMID: 12754504
  40. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element.
    Mol Cell Biol. 2004 Jan;24(2):787-95 PMID: 14701750
  41. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling.
    Genes Dev. 2008 May 15;22(10):1356-68 PMID: 18483222
  42. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.
    J Clin Invest. 2005 Nov;115(11):3250-5 PMID: 16276421
  43. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation.
    Mol Cell Biol. 2002 Jul;22(13):4622-37 PMID: 12052871
  44. An inducible transcription factor activates expression of human immunodeficiency virus in T cells.
    Nature. 1987 Apr 16-22;326(6114):711-3 PMID: 3031512
  45. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Science. 1997 Nov 14;278(5341):1295-300 PMID: 9360927
  46. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells.
    J Virol. 2009 Jun;83(12):6222-33 PMID: 19369341
  47. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.
    J Virol. 2010 Sep;84(17):8712-20 PMID: 20538859
  48. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat.
    J Biol Chem. 1998 Sep 18;273(38):24898-905 PMID: 9733796
  49. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes.
    Nature. 2001 Nov 15;414(6861):322-5 PMID: 11713533
  50. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.
    Blood. 2009 Jan 1;113(1):58-65 PMID: 18849485
  51. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
    Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14 PMID: 10611346
  52. Transient-mediated fate determination in a transcriptional circuit of HIV.
    Nat Genet. 2008 Apr;40(4):466-70 PMID: 18344999
  53. HIV rebounds from latently infected cells, rather than from continuing low-level replication.
    Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16725-30 PMID: 18936487
  54. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.
    Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13519-24 PMID: 9811832
  55. CpG methylation controls reactivation of HIV from latency.
    PLoS Pathog. 2009 Aug;5(8):e1000554 PMID: 19696893
  56. Control of stochastic gene expression by host factors at the HIV promoter.
    PLoS Pathog. 2009 Jan;5(1):e1000260 PMID: 19132086
  57. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation.
    J Biol Chem. 2001 Apr 20;276(16):12951-8 PMID: 11112772
  58. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294.
    J Biol Chem. 2010 May 28;285(22):16538-45 PMID: 20335163
  59. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.
    EMBO J. 1993 Aug;12(8):3249-59 PMID: 8344262
  60. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription.
    Nature. 2001 Nov 15;414(6861):317-22 PMID: 11713532
  61. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor.
    EMBO J. 2004 Jul 7;23(13):2608-19 PMID: 15201869
  62. Domains in the SPT5 protein that modulate its transcriptional regulatory properties.
    Mol Cell Biol. 2000 May;20(9):2970-83 PMID: 10757782
  63. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells.
    Immunity. 1997 Mar;6(3):235-44 PMID: 9075924
  64. Re-emergence of HIV after stopping therapy.
    Nature. 1999 Oct 28;401(6756):874-5 PMID: 10553903
  65. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
    Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8 PMID: 19470482
  66. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.
    J Virol. 2003 Apr;77(8):4938-49 PMID: 12663799
  67. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.
    EMBO J. 2007 Dec 12;26(24):4985-95 PMID: 18007589
  68. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1.
    Science. 1986 May 9;232(4751):755-9 PMID: 3008338
  69. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.
    Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12955-60 PMID: 14569007
  70. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
    J Clin Invest. 2009 Nov;119(11):3473-86 PMID: 19805909
  71. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP.
    Mol Cell. 2010 May 14;38(3):439-51 PMID: 20471949
  72. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex.
    J Biol Chem. 2007 Jun 8;282(23):16981-8 PMID: 17442680
  73. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA.
    Mol Cell. 2003 Oct;12(4):971-82 PMID: 14580347
  74. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.
    EMBO J. 2007 Jan 24;26(2):424-35 PMID: 17245432
  75. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.
    Virology. 2009 Apr 25;387(1):98-108 PMID: 19268337
  76. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.
    J Virol. 2005 Jun;79(11):6610-9 PMID: 15890899
  77. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.
    Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):46-51 PMID: 20080798
  78. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.
    J Virol. 1991 Aug;65(8):4350-8 PMID: 2072454
  79. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.
    J Mol Biol. 1995 May 5;248(3):562-80 PMID: 7752225
  80. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.
    Cell Host Microbe. 2008 Aug 14;4(2):134-46 PMID: 18692773
  81. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.
    J Virol. 2009 May;83(10):4749-56 PMID: 19279091
  82. The challenge of finding a cure for HIV infection.
    Science. 2009 Mar 6;323(5919):1304-7 PMID: 19265012
  83. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    AIDS. 2009 Sep 10;23(14):1799-806 PMID: 19590405
  84. Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element.
    Nat Struct Biol. 2003 Oct;10(10):800-6 PMID: 12949493
  85. The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth.
    J Virol. 1997 Jul;71(7):5495-504 PMID: 9188623
  86. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency.
    J Virol. 2008 Dec;82(24):12291-303 PMID: 18829756
Article Info
Journal
Current opinion in HIV and AIDS
Abbr.
Curr Opin HIV AIDS
ISSN
1746-6318
Published
2011-01-00
Pages
4-11
Language
English
Region
United States
NLM ID
101264945
PMCID
PMC3032057
Subset
IM
Grants
NIAID NIH HHS · R01 AI067093-04 · United States
NIDA NIH HHS · DP1 DA028869-01 · United States
NIDA NIH HHS · DP1 DA028869 · United States
NIDA NIH HHS · DP1-DA028869 · United States
NIAID NIH HHS · R01 AI067093 · United States
NIAID NIH HHS · R01-AI067093 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com